- Home
- QUIK vs SAVA Comparison
QUIK vs SAVA Comparison
Compare QUIK & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUIK
- SAVA
- Stock Information
- Founded
- QUIK 1988
- SAVA 1998
- Country
- QUIK United States
- SAVA United States
- Employees
- QUIK N/A
- SAVA N/A
- Industry
- QUIK Semiconductors
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- QUIK Technology
- SAVA Health Care
- Exchange
- QUIK Nasdaq
- SAVA Nasdaq
- Market Cap
- QUIK 100.1M
- SAVA 102.4M
- IPO Year
- QUIK 1997
- SAVA N/A
- Fundamental
- Price
- QUIK $5.62
- SAVA $2.11
- Analyst Decision
- QUIK Strong Buy
- SAVA Hold
- Analyst Count
- QUIK 3
- SAVA 1
- Target Price
- QUIK $10.87
- SAVA $2.00
- AVG Volume (30 Days)
- QUIK 179.8K
- SAVA 518.9K
- Earning Date
- QUIK 11-10-2025
- SAVA 11-06-2025
- Dividend Yield
- QUIK N/A
- SAVA N/A
- EPS Growth
- QUIK N/A
- SAVA N/A
- EPS
- QUIK N/A
- SAVA N/A
- Revenue
- QUIK $18,359,000.00
- SAVA N/A
- Revenue This Year
- QUIK $11.58
- SAVA N/A
- Revenue Next Year
- QUIK $22.73
- SAVA N/A
- P/E Ratio
- QUIK N/A
- SAVA N/A
- Revenue Growth
- QUIK N/A
- SAVA N/A
- 52 Week Low
- QUIK $4.26
- SAVA $1.15
- 52 Week High
- QUIK $13.36
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- QUIK 52.32
- SAVA 44.15
- Support Level
- QUIK $5.00
- SAVA $2.12
- Resistance Level
- QUIK $5.56
- SAVA $2.19
- Average True Range (ATR)
- QUIK 0.24
- SAVA 0.10
- MACD
- QUIK 0.06
- SAVA -0.02
- Stochastic Oscillator
- QUIK 91.11
- SAVA 6.45
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.